Point72 Hong Kong LTD Abb Vie Inc. Transaction History

Point72 Hong Kong LTD

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $12.5 Million - $14.1 Million	90,858 New	90,858 $14.1 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $5.67 Million - $7.21 Million	-41,184 Reduced 77.01%	12,293 $1.88 Million
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $827,646 - $1.03 Million	6,271 Added 13.28%	53,477 $8.67 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $4.45 Million - $5.63 Million	-41,420 Reduced 46.74%	47,206 $6.39 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $4.01 Million - $4.55 Million	37,661 Added 73.9%	88,626 $9.56 Million
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $1.59 Million - $1.76 Million	-15,584 Reduced 23.42%	50,965 $5.52 Million
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $5.36 Million - $7.23 Million	66,549 New	66,549 $7.13 Million
Q1 2020 May 15, 2020	SELL	$64.5 - $97.79 $418,669 - $634,754	-6,491 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $468,195 - $585,812	6,491 New	6,491 $575,000
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $526,421 - $649,219	-6,762 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $601,209 - $668,356	6,762 New	6,762 $640,000
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $418,464 - $495,138	-4,661 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $428,122 - $573,296	4,653 Added 58162.5%	4,661 $441,000
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $151,087 - $165,680	-1,687 Reduced 99.53%	8 $1,000
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $118,395 - $151,227	1,695	1,695 $151,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.